Katherine Aguirre-Guataqui
Katherine Aguirre-Guataqui has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Andres Ceballos-Garzon
Studies in Translational Microbiology and Emerging Diseases (MICROS) Research Group, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia
2 shared publications - Claudia Marcela Parra Giraldo
Unidad de Proteómica y Micosis Humanas, Grupo de Enfermedades Infecciosas, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Carrera 7 No. 43-82, Bogotá D.C. 110231, Colombia, Colombia
2 shared publications Adriana Piza-Buitrago
Laboratorio Clínico Especializado, Clínica Universitaria Colombia, Grupo Keralty, Bogotá, Colombia
1 shared publication- Aura León
Laboratorio clínico, Área de Microbiología, Hospital Universitario San Ignacio, Bogotá D.C, Colombia
1 shared publication - Beatriz Ariza
Hospital Universitario San Ignacio, Grupo de Investigación en Ciencias de Laboratorio Clínico, Hospital Universitario San Ignacio; Grupo de Investigación de Enfermedades Infecciosas. Bogotá, Colombia
1 shared publication - Erika Cabrera
Laboratorio clínico, Área de Microbiología, Hospital Universitario San Ignacio, Bogotá D.C, Colombia
1 shared publication
Latest Publications
- Open Access
- 6 December 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 53, 101321
Genomic landscape of hereditary cancer syndromes in the largest cohort in Colombia: a retrospective study
- 6 December 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 53, 101321
Open AccessGenomic landscape of hereditary cancer syndromes in the largest cohort in Colombia: a retrospective study
- Open Access
- 5 November 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (11) , 1561
Chimeric Peptides Derived from Bovine Lactoferricin and Buforin II: Antifungal Activity against Reference Strains and Clinical Isolates of Candida spp.
Antimicrobial peptides (AMPs) are considered to be a valuable source for the identification and/or design of promising candidates for the development of antifungal treatments, since they have advantages such as lower tendency to induce resistance, ease of production, and high purity and safety. Bovine lactoferricin (LfcinB) and Buforin II (BFII) are AMPs to which great antimicrobial potential has been attributed. The minimum motives with antimicrobial activity derived from LfcinB and BFII are RRWQWR and RLLR, respectively. Nine chimeras containing the minimum motives of both peptides were synthesized and their antifungal activity against fluconazole (FLC)-sensitive and resistant C. albicans, C. glabrata, and C. auris strains was evaluated. The results showed that peptides C9: (RRWQWR)2K-Ahx-RLLRRRLLR and C6: KKWQWK-Ahx-RLLRRLLR exhibited the greatest antifungal activity against two strains of C. albicans, a FLC-sensitive reference strain and a FLC-resistant clinical isolate; no medically significant results were observed with the other chimeras evaluated (MIC ~200 μg/mL). The chimera C6 was also active against sensitive and resistant strains of C. glabrata and C. auris. The combination of branched polyvalent chimeras together with FLC showed a synergistic effect against C. albicans. In addition to exhibiting antifungal activity against reference strains and clinical isolates of Candida spp., they also showed antibacterial activity against both Gram-positive and Gram-negative bacteria, suggesting that these chimeras exhibit a broad antimicrobial spectrum and can be considered to be promising molecules for therapeutic applications.
- 5 November 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (11) , 1561
Open AccessChimeric Peptides Derived from Bovine Lactoferricin and Buforin II: Antifungal Activity against Reference Strains and Clinical Isolates of Candida spp.
Antimicrobial peptides (AMPs) are considered to be a valuable source for the identification and/or design of promising candidates for the development of antifungal treatments, since they have advantages such as lower tendency to induce resistance, ease of production, and high purity and safety. Bovine lactoferricin (LfcinB) and Buforin II (BFII) are AMPs to which great antimicrobial potential has been attributed. The minimum motives with antimicrobial activity derived from LfcinB and BFII are RRWQWR and RLLR, respectively. Nine chimeras containing the minimum motives of both peptides were synthesized and their antifungal activity against fluconazole (FLC)-sensitive and resistant C. albicans, C. glabrata, and C. auris strains was evaluated. The results showed that peptides C9: (RRWQWR)2K-Ahx-RLLRRRLLR and C6: KKWQWK-Ahx-RLLRRLLR exhibited the greatest antifungal activity against two strains of C. albicans, a FLC-sensitive reference strain and a FLC-resistant clinical isolate; no medically significant results were observed with the other chimeras evaluated (MIC ~200 μg/mL). The chimera C6 was also active against sensitive and resistant strains of C. glabrata and C. auris. The combination of branched polyvalent chimeras together with FLC showed a synergistic effect against C. albicans. In addition to exhibiting antifungal activity against reference strains and clinical isolates of Candida spp., they also showed antibacterial activity against both Gram-positive and Gram-negative bacteria, suggesting that these chimeras exhibit a broad antimicrobial spectrum and can be considered to be promising molecules for therapeutic applications.
- Open Access
- 1 December 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 101, 85-89
In-house protocol and performance of MALDI-TOF MS in the early diagnosis of bloodstream infections in a fourth-level hospital in Colombia: Jumping to full use of this technology
- 1 December 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 101, 85-89
Open AccessIn-house protocol and performance of MALDI-TOF MS in the early diagnosis of bloodstream infections in a fourth-level hospital in Colombia: Jumping to full use of this technology